|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||g·mol−1 422.451|
|3D model (JSmol)|
Potential common adverse effects include thermohypoesthesia, chills, feeling cold, and feeling hot.
When administered orally once a day, mavatrep reached steady-state in healthy volunteers in approximately 14 days. It has a relatively long half life between 68–101 hours in Japanese subjects and between 82–130 hours in Caucasian subjects.
Mavatrep is largely eliminated nonrenally. Mavatrep appears to be metabolized into two primary metabolites which are also eliminated nonrenally.
- Manitpisitkul, Prasarn; Shalayda, Kevin; Russell, Lucille; Sanga, Panna; Williams, Yinka; Solanki, Bhavna; Caruso, Joseph; Moyer, John A. (2018). “Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies”. Clinical Pharmacology in Drug Development. 7 (7): 699–711. doi:10.1002/cpdd.412. ISSN 2160-7648.
- Manitpisitkul, Prasarn; Shalayda, Kevin; Russell, Lucille; Sanga, Panna; Solanki, Bhavna; Caruso, Joseph; Iwaki, Yuki; Moyer, John A. (2018). “Pharmacokinetics and Safety of Mavatrep (JNJ-39439335), a TRPV1 Antagonist in Healthy Japanese and Caucasian Men: A Double-Blind, Randomized, Placebo-Controlled, Sequential-Group Phase 1 Study”. Clinical Pharmacology in Drug Development. 7 (7): 712–726. doi:10.1002/cpdd.413. ISSN 2160-7648.